• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·PFE
Held by 4 Gurus
Share

Pfizer Inc. Stocks

$ 29.36Last Updated 10.11.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 167.29B

$ 29.36
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Michael Burry

Portfolio Weight (%)

11.1%

Change

+11.07%

Fund

Scion Asset Management

Steven Cohen

Portfolio Weight (%)

0.1%

Change

-0.14%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.1%

Change

-0.03%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Michael BurryScion Asset Management11.1%+11.07%
Steven CohenPoint72 Asset Management, L.P.0.1%-0.14%
Kenneth GriffinCITADEL ADVISORS LLC0.1%-0.03%
Show more

Latest news

04.11.2026 00:20

Pfizer Raises Annual Revenue Forecast: It Has Found New Sources of Growth in the Wake of COVID

03.11.2026 15:26

Morning in New York: The market is under pressure from Apple's earnings report and is awaiting the election results

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

09.10.2026 17:15

Pacira soars 44% as Viatris agrees to buy biotech to boost non-opioid pain portfolio

09.10.2026 15:00

TRex Bio IPO: LLY-backed biotech focused on autoimmune, inflammatory diseases debuts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of PFE is 29.1 and suggests 0.886% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.11.2026 11:41

Morning Highlights: Nvidia Seeks a Replacement for Huang, Competitors' Stocks Rise, CoreWeave Deal

12.11.2026 11:31

Musk called it an honor to have the opportunity to hire the head of Nvidia, who faces dismissal

12.11.2026 10:58

"A Recipe for a Crash": Wall Street Estimates How Much Nvidia's Stock Could Be Worth Without Huang

12.11.2026 10:11

Nvidia has hired headhunters to find a replacement for Huang. Among the candidates is a top Apple executive.

12.11.2026 03:37

Nvidia is preparing to oust Huang — WSJ. Analysts had expected a drop of up to 30% in this scenario

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026